|Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy|
R Seiler, HAD Ashab, N Erho, BWG van Rhijn, B Winters, J Douglas, ...
European urology 72 (4), 544-554, 2017
|Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial|
J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ...
The lancet oncology 21 (1), 162-174, 2020
|Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial|
T Powles, M Kockx, A Rodriguez-Vida, I Duran, SJ Crabb, ...
Nature medicine 25 (11), 1706-1714, 2019
|Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer|
KJ Pienta, JP Machiels, D Schrijvers, B Alekseev, M Shkolnik, SJ Crabb, ...
Investigational new drugs 31, 760-768, 2013
|Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …|
T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020
|Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group|
G Ryan, G Martinelli, M Kuper-Hommel, R Tsang, G Pruneri, K Yuen, ...
Annals of Oncology 19 (2), 233-241, 2008
|Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised …|
DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ...
The Lancet 390 (10109), 2266-2277, 2017
|IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre …|
BI Rini, A Stenzl, R Zdrojowy, M Kogan, M Shkolnik, S Oudard, S Weikert, ...
The Lancet Oncology 17 (11), 1599-1611, 2016
|Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer|
SJ Crabb, MCU Cheang, S Leung, T Immonen, TO Nielsen, ...
Clinical breast cancer 8 (3), 249-256, 2008
|Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer|
MD Galsky, SK Pal, S Chowdhury, LC Harshman, SJ Crabb, YN Wong, ...
Cancer 121 (15), 2586-2593, 2015
|Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor …|
T Powles, RA Huddart, T Elliott, SJ Sarker, C Ackerman, R Jones, ...
Journal of Clinical Oncology 35 (1), 48-55, 2017
|Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised …|
G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, ...
The lancet 399 (10323), 447-460, 2022
|Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non–small-cell lung cancer|
SJ Crabb, D Patsios, E Sauerbrei, PM Ellis, A Arnold, G Goss, NB Leighl, ...
Journal of Clinical Oncology 27 (3), 404-410, 2009
|EAU-ESMO Consensus statements on the management of advanced and variant bladder cancer—an international collaborative multistakeholder effort†: under the auspices of the EAU …|
JA Witjes, M Babjuk, J Bellmunt, HM Bruins, TM De Reijke, M De Santis, ...
European urology 77 (2), 223-250, 2020
|Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib|
C Lolli, U Basso, L Derosa, E Scarpi, T Sava, M Santoni, SJ Crabb, ...
Oncotarget 7 (34), 54564, 2016
|Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors|
H Benelkebir, C Hodgkinson, PJ Duriez, AL Hayden, RA Bulleid, ...
Bioorganic & medicinal chemistry 19 (12), 3709-3716, 2011
|Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery|
A Ganesan, L Nolan, SJ Crabb, G Packham
Current Cancer Drug Targets 9 (8), 963-981, 2009
|S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase …|
A Hayden, PWM Johnson, G Packham, SJ Crabb
Breast cancer research and treatment 127, 109-119, 2011
|Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?|
L Nolan, PWM Johnson, A Ganesan, G Packham, SJ Crabb
British journal of cancer 99 (5), 689-694, 2008
|A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).|
T Powles, A Rodriguez-Vida, I Duran, SJ Crabb, MS Van Der Heijden, ...
Journal of Clinical Oncology 36 (15_suppl), 4506-4506, 2018